{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:48:58Z","timestamp":1792586938555,"version":"4.5.0"},"reference-count":145,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1053\/j.semnuclmed.2026.05.005","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:02:38Z","timestamp":1780372958000},"page":"759-775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Maximizing diagnostic yield: A systematic review and deep dive into PSMA PET scan protocol variations for prostate cancer"],"prefix":"10.1053","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6470-4096","authenticated-orcid":false,"given":"Sajjad","family":"Sadeghpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6514-0720","authenticated-orcid":false,"given":"Bahare","family":"Saidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8772-2502","authenticated-orcid":false,"given":"Pegah","family":"Sahafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1627-7479","authenticated-orcid":false,"given":"Faezeh","family":"Maleki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7806-7921","authenticated-orcid":false,"given":"Shaghayegh","family":"Ranjbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Ghorbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6797-8471","authenticated-orcid":false,"given":"Hakime","family":"Ghadiri Hakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1351-3142","authenticated-orcid":false,"given":"Atena","family":"Aghaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1486-2624","authenticated-orcid":false,"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3918-3812","authenticated-orcid":false,"given":"Mohsen","family":"Beheshti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2973-2251","authenticated-orcid":false,"given":"Emran","family":"Askari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0001","doi-asserted-by":"crossref","unstructured":"Cornford P., Van den Bergh R.C., Briers E., et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol 86(2):148-163, 2024","DOI":"10.1016\/j.eururo.2024.03.027"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.05.005_bib0002","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00432-025-06184-z","article-title":"PSMA PET\/CT for prostate cancer diagnosis: current applications and future directions","volume":"151","author":"Shen","year":"2025","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.05.005_bib0003","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0005","unstructured":"FDA. FDA approves second PSMA-targeted PET imaging drug for men with prostate cancer. 2021."},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.05.005_bib0006","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0007","first-page":"26","article-title":"SNMMI procedure standard\/EANM practice guideline for fibroblast activation protein (FAP) PET","author":"Hope","year":"2024","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.05.005_bib0008","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2025.08.005","article-title":"SPARC: the standardised prostate-specific membrane antigen positron emission tomography\/computed tomography analysis and reporting consensus: a Delphi analysis","volume":"89","author":"Herrmann","year":"2026","journal-title":"Eur Urol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0009","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s00261-025-05068-7","article-title":"PSMA-RADS 2.0: a revised framework for PSMA-targeted imaging interpretation and clinical decision-making","volume":"51","author":"Elsamny","year":"2026","journal-title":"Abdom Radiol (NY)"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.05.005_bib0010","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.05.005_bib0011","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0012","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40644-024-00702-x","volume":"24","author":"Ayati","year":"2024","journal-title":"Cancer Imaging"},{"issue":"11","key":"10.1053\/j.semnuclmed.2026.05.005_bib0013","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.3390\/diagnostics12112594","article-title":"PSMA PET-CT in the diagnosis and staging of prostate cancer","volume":"12","author":"Combes","year":"2022","journal-title":"Diagnostics"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0014","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/life14010076","article-title":"A systematic review on prostate-specific membrane antigen positron emission tomography (PSMA PET) evaluating localized low- to intermediate-risk prostate cancer: a tool to improve risk stratification for active surveillance?","volume":"14","author":"Liu","year":"2024","journal-title":"Life"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.05.005_bib0015","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/02841851241307336","article-title":"Comparative diagnostic performance of (68)Ga-PSMA-11 PET\/CT and (68)Ga-PSMA-11 PET\/MRI in detecting biochemical recurrent bone metastasis in prostate cancer: a systematic review and meta-analysis","volume":"66","author":"Wen","year":"2025","journal-title":"Acta Radiol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.05.005_bib0016","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4103\/aja202162","article-title":"The performance of (18)F-PSMA PET\/CT in the detection of prostate cancer: a systematic review and meta-analysis","volume":"24","author":"Qin","year":"2022","journal-title":"Asian J Androl"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0017","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40644-020-0290-9","article-title":"PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review","volume":"20","author":"Petersen","year":"2020","journal-title":"Cancer Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0018","article-title":"Beyond the standard: enhancing prostate bed and regional lymph node detection in prostate cancer patients with early and delayed imaging in [68 Ga] Ga-PSMA-11 PET\/CT","volume":"45","author":"Aghaee","year":"2026","journal-title":"Revista Espa\u00f1ola Medicina Nucl Imagen Molecular (Engl Edit)"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0019","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s00259-018-3970-y","article-title":"Optimal time-point for 68 Ga-PSMA-11 PET\/CT imaging in assessment of prostate cancer: feasibility of sterile cold-kit tracer preparation?","volume":"45","author":"Beheshti","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.05.005_bib0020","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1007\/s00259-021-05659-8","article-title":"Determination of optimal (68) Ga-PSMA PET\/CT imaging time in prostate cancers by total-body dynamic PET\/CT","volume":"49","author":"Wen","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.05.005_bib0021","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s00259-021-05539-1","article-title":"Head-to-head comparison of [(68) Ga]Ga-P16-093 and [(68) Ga]Ga-PSMA-617 in dynamic PET\/CT evaluation of the same group of recurrent prostate cancer patients","volume":"49","author":"Wang","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.05.005_bib0022","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4103\/ijnm.IJNM_32_18","article-title":"Can early dynamic positron emission tomography\/computed tomography obviate the need for postdiuresis image in (68)Ga-PSMA-HBED-CC scan for evaluation of prostate adenocarcinoma?","volume":"33","author":"Perveen","year":"2018","journal-title":"Indian J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.05.005_bib0023","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4103\/ijnm.IJNM_8_18","article-title":"Role of early dynamic positron emission tomography\/computed tomography with 68Ga-prostate-specific membrane antigen-HBED-CC in patients with adenocarcinoma prostate: initial results","volume":"33","author":"Perveen","year":"2018","journal-title":"Indian J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.05.005_bib0024","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1097\/RLU.0000000000001589","article-title":"Multiple time-point 68Ga-PSMA I&T PET\/CT for characterization of primary prostate cancer: value of early dynamic and delayed imaging","volume":"42","author":"Schmuck","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.05.005_bib0025","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00259-016-3578-z","article-title":"Early dynamic imaging in (68)Ga- PSMA-11 PET\/CT allows discrimination of urinary bladder activity and prostate cancer lesions","volume":"44","author":"Uprimny","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1053\/j.semnuclmed.2026.05.005_bib0026","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.3390\/cancers12102788","article-title":"Dual-time point [68Ga] Ga-PSMA-11 PET\/CT hybrid imaging for staging and restaging of prostate cancer","volume":"12","author":"Hoffmann","year":"2020","journal-title":"Cancers"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.05.005_bib0027","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.3390\/jcm11123311","article-title":"Ga-68-PSMA-11 PET\/CT in patients with biochemical recurrence of prostate cancer after primary treatment with curative intent\u2014Impact of delayed imaging","volume":"11","author":"Kunikowska","year":"2022","journal-title":"J Clin Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.05.005_bib0028","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/1754-9485.12625","article-title":"Frusemide aids diagnostic interpretation of 68Ga-PSMA positron emission tomography\/CT in men with prostate cancer","volume":"61","author":"Fennessy","year":"2017","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0029","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s00259-019-04548-5","article-title":"68 Ga-PSMA-11 PET\/CT in patients with recurrent prostate cancer\u2014a modified protocol compared with the common protocol","volume":"47","author":"Haupt","year":"2020","journal-title":"Eur j nucl med mol imaging"},{"issue":"8","key":"10.1053\/j.semnuclmed.2026.05.005_bib0030","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/jlcr.3745","article-title":"Dual-time-point 64 Cu-PSMA-617-PET\/CT in patients suffering from prostate cancer","volume":"62","author":"Hober\u00fcck","year":"2019","journal-title":"J Label Compd Radiopharm"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.05.005_bib0031","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s00259-021-05539-1","article-title":"Head-to-head comparison of [68 Ga] Ga-P16-093 and [68 Ga] Ga-PSMA-617 in dynamic PET\/CT evaluation of the same group of recurrent prostate cancer patients","volume":"49","author":"Wang","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0032","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13550-023-00981-8","article-title":"Multiparametric dynamic whole-body PSMA PET\/CT using [68Ga] Ga-PSMA-11 and [18F] PSMA-1007","volume":"13","author":"Dias","year":"2023","journal-title":"EJNMMI res"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0033","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13550-022-00913-y","article-title":"Effects of furosemide and tracer selection on urinary activity and peri-bladder artefacts in PSMA PET\/CT: a single-centre retrospective study","volume":"12","author":"Donswijk","year":"2022","journal-title":"EJNMMI res"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.05.005_bib0034","first-page":"355","article-title":"Dual-phase 68Ga-PSMA-11 PET\/CT may increase the rate of detected lesions in prostate cancer patients","volume":"88","author":"Dadgar","year":"2021","journal-title":"Urol J"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.05.005_bib0035","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/MNM.0000000000000290","article-title":"Evaluation of PSMA PET\/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging","volume":"36","author":"Kabasakal","year":"2015","journal-title":"Nucl Med Commun"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.05.005_bib0036","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4103\/ijnm.IJNM_8_18","article-title":"Role of early dynamic positron emission tomography\/computed tomography with 68Ga-prostate-specific membrane antigen-HBED-CC in patients with adenocarcinoma prostate: initial results","volume":"33","author":"Perveen","year":"2018","journal-title":"Indian J Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2026.05.005_bib0037","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00259-017-3743-z","article-title":"Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence","volume":"44","author":"Uprimny","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"14","key":"10.1053\/j.semnuclmed.2026.05.005_bib0038","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.3390\/molecules27144661","article-title":"Super early scan of PSMA PET\/CT in evaluating primary and metastatic lesions of prostate cancer","volume":"27","author":"Mao","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0039","doi-asserted-by":"crossref","first-page":"8297","DOI":"10.1038\/s41598-023-35628-0","article-title":"Diagnostic value of two-time point [(68)Ga]Ga-PSMA-11 PET\/CT in the primary staging of untreated prostate cancer","volume":"13","author":"Weitzer","year":"2023","journal-title":"Sci Rep"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-020-00735-w","article-title":"Kinetic analysis of dominant intraprostatic lesion of prostate cancer using quantitative dynamic [18 F] DCFPyL-PET: comparison to [18 F] fluorocholine-PET","volume":"11","author":"Yang","year":"2021","journal-title":"EJNMMI Res"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0041","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1038\/s41598-020-59296-6","article-title":"Role of early PET\/CT imaging with 68Ga-PSMA in staging and restaging of prostate cancer","volume":"10","author":"Barakat","year":"2020","journal-title":"Sci Rep"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0042","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00259-016-3578-z","article-title":"Early dynamic imaging in 68 Ga-PSMA-11 PET\/CT allows discrimination of urinary bladder activity and prostate cancer lesions","volume":"44","author":"Uprimny","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0043","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00259-017-3743-z","article-title":"Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence","volume":"44","author":"Uprimny","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1053\/j.semnuclmed.2026.05.005_bib0044","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3390\/diagnostics11071191","article-title":"Comparison of early imaging and imaging 60 min post-injection after forced diuresis with furosemide in the assessment of local recurrence in prostate cancer patients with biochemical recurrence referred for 68Ga-PSMA-11 PET\/CT","volume":"11","author":"Bayerschmidt","year":"2021","journal-title":"Diagnostics"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.05.005_bib0045","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.remn.2018.06.006","article-title":"Efficacy of early imaging with 68Ga-PSMA I&T in the discrimination of pelvic lesions in prostate cancer patients","volume":"38","author":"\u00d6z\u00fclker","year":"2019","journal-title":"Revista Espa\u00f1ola de Medicina Nucl Imagen Mol (Engl Edit)"},{"issue":"7","key":"10.1053\/j.semnuclmed.2026.05.005_bib0046","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s00259-018-3970-y","article-title":"Optimal time-point for 68Ga-PSMA-11 PET\/CT imaging in assessment of prostate cancer: feasibility of sterile cold-kit tracer preparation?","volume":"45","author":"Beheshti","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1053\/j.semnuclmed.2026.05.005_bib0047","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.2967\/jnumed.117.192658","article-title":"18F-DCFPyL PET\/CT in the detection of prostate cancer at 60 and 120 minutes: detection rate, image quality, activity kinetics, and biodistribution","volume":"58","author":"Wondergem","year":"2017","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.05.005_bib0048","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12149-019-01428-8","article-title":"Contribution of 5th minute and 2nd hour images to standard imaging in (68Ga) PSMA 11 PET\/CT","volume":"34","author":"Can","year":"2020","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0049","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","article-title":"PET imaging with a [68 Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions","volume":"40","author":"Afshar-Oromieh","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1053\/j.semnuclmed.2026.05.005_bib0050","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","article-title":"The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET\/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions","volume":"56","author":"Afshar-Oromieh","year":"2015","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.05.005_bib0051","doi-asserted-by":"crossref","first-page":"750","DOI":"10.2967\/jnumed.116.183483","article-title":"The clinical impact of additional late PET\/CT imaging with 68Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer","volume":"58","author":"Afshar-Oromieh","year":"2017","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1053\/j.semnuclmed.2026.05.005_bib0052","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.2967\/jnumed.120.257741","article-title":"Combination of forced diuresis with additional late imaging in 68Ga-PSMA-11 PET\/CT: effects on lesion visibility and radiotracer uptake","volume":"62","author":"Alberts","year":"2021","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0053","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13550-022-00938-3","article-title":"Evaluation of [68 Ga] Ga-PSMA-I&T PET\/CT with additional late scans of the pelvis in prostate-specific antigen recurrence using the PROMISE criteria","volume":"12","author":"Koehler","year":"2022","journal-title":"EJNMMI Res"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.05.005_bib0054","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1007\/s00259-021-05659-8","article-title":"Determination of optimal 68 Ga-PSMA PET\/CT imaging time in prostate cancers by total-body dynamic PET\/CT","volume":"49","author":"Wen","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.05.005_bib0055","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1007\/s00330-023-09516-0","article-title":"Combined forced diuresis and late acquisition on [68Ga] Ga-PSMA-11 PET\/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study","volume":"33","author":"Bauckneht","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0056","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","article-title":"F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients","volume":"44","author":"Giesel","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0057","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41824-023-00167-4","article-title":"PET\/CT imaging 2 h after injection of [18F] PSMA-1007 can lead to higher staging of prostate cancer than imaging after 1 h","volume":"7","author":"Hvittfeldt","year":"2023","journal-title":"Eur j hybrid imaging"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.05.005_bib0058","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.3390\/biomedicines11041052","article-title":"Diagnostic impact of dual-time PET\/CT with 68Gallium-PSMA in prostate cancer and 68Gallium-DOTATOC in neuroendocrine tumors","volume":"11","author":"Librizzi","year":"2023","journal-title":"Biomedicines"},{"issue":"10","key":"10.1053\/j.semnuclmed.2026.05.005_bib0059","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.2967\/jnumed.119.238071","article-title":"Multiphasic <sup>68<\/sup>Ga-PSMA PET\/CT in the detection of early recurrence in prostate cancer patients with a PSA level of less than 1 ng\/mL: a prospective study of 135 patients","volume":"61","author":"Beheshti","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0060","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s11307-018-1263-2","article-title":"Combined early and late [68 Ga] PSMA-HBED-CC PET scans improve lesion detectability in biochemical recurrence of prostate cancer with low PSA levels","volume":"21","author":"Hohberg","year":"2019","journal-title":"Mol Imaging Biol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.05.005_bib0061","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1007\/s00259-017-3669-5","article-title":"Comparison of standard and delayed imaging to improve the detection rate of [(68)Ga]PSMA I&T PET\/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer","volume":"44","author":"Schmuck","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1053\/j.semnuclmed.2026.05.005_bib0062","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s12149-023-01864-7","article-title":"Enhancing PSMA PET\/CT imaging of prostate cancer: investigating the impact of multiple time point evaluation, diuretic administration, cribriform pattern, and intraductal carcinoma","volume":"37","author":"Guner","year":"2023","journal-title":"Ann Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2026.05.005_bib0063","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/jlcr.3745","article-title":"Dual-time-point (64) Cu-PSMA-617-PET\/CT in patients suffering from prostate cancer","volume":"62","author":"Hober\u00fcck","year":"2019","journal-title":"J Label Comp Radiopharm"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0064","first-page":"11","article-title":"Role of (18)F-DCFPyL PET\/CT in patients with suspected prostate cancer","volume":"25","author":"Zhang","year":"2022","journal-title":"Hell J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.05.005_bib0065","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1007\/s00259-017-3669-5","article-title":"Comparison of standard and delayed imaging to improve the detection rate of [68Ga] PSMA I&T PET\/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer","volume":"44","author":"Schmuck","year":"2017","journal-title":"Eur j nucl med mol imaging"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.05.005_bib0066","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.31557\/APJCP.2020.21.12.3719","article-title":"Incremental value of post diuretic 68Ga-PSMA-11 PET-CT in characterization of indeterminate lLesions in prostate cancer","volume":"21","author":"Ghadanfer","year":"2020","journal-title":"Asian Pac J Cancer Prev: APJCP"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.05.005_bib0067","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1007\/s00330-016-4308-4","article-title":"68Ga-PSMA I&T PET\/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging","volume":"26","author":"Derlin","year":"2016","journal-title":"Eur radiol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0068","first-page":"1","article-title":"Improved accuracy and reliability of PRIMARY scoring using delayed [68Ga] Ga-PSMA PET\/CT imaging","volume":"34","author":"Ak\u00e7ay","year":"2025","journal-title":"Mol Imaging Radionucl Ther"},{"issue":"13","key":"10.1053\/j.semnuclmed.2026.05.005_bib0069","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1007\/s00259-021-05426-9","article-title":"64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer","volume":"48","author":"Liu","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.05.005_bib0070","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s12149-023-01823-2","article-title":"Multi-timepoint imaging with PSMA-targeted [18F] F-florastamin PET\/CT: lesion detection and comparison to conventional imaging","volume":"37","author":"Sheikhbahaei","year":"2023","journal-title":"Ann Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0071","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s41824-025-00268-2","article-title":"Characterization of suspicious prostate lesions at multiparametric MRI with dynamic 68 Ga-gozetotide PET\/CT","volume":"9","author":"Parrott","year":"2025","journal-title":"EJNMMI rep"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0072","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13550-021-00757-y","article-title":"Potential synergy between PSMA uptake and tumour blood flow for prediction of human prostate cancer aggressiveness","volume":"11","author":"Jochumsen","year":"2021","journal-title":"EJNMMI res"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0073","doi-asserted-by":"crossref","first-page":"449","DOI":"10.21873\/anticanres.16181","article-title":"Assessment of prostate carcinoma aggressiveness: relation to 68Ga-PSMA-11-PET\/MRI and Gleason score","volume":"43","author":"Ferda","year":"2023","journal-title":"Anticancer Res"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.05.005_bib0074","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s00259-018-4079-z","article-title":"Impact of long-term androgen deprivation therapy on PSMA ligand PET\/CT in patients with castration-sensitive prostate cancer","volume":"45","author":"Afshar-Oromieh","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1053\/j.semnuclmed.2026.05.005_bib0075","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.3390\/diagnostics15111400","article-title":"Optimizing attenuation correction in 68Ga-PSMA PET imaging using deep learning and artifact-free dataset refinement","volume":"15","author":"Dorri Giv","year":"2025","journal-title":"Diagnostics"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.05.005_bib0076","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s12149-021-01705-5","article-title":"Dual time point imaging of staging PSMA PET\/CT quantification; spread and radiomic analyses","volume":"36","author":"Aksu","year":"2022","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0077","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00259-019-04545-8","article-title":"Dynamic patterns of [68 Ga] Ga-PSMA-11 uptake in recurrent prostate cancer lesions","volume":"47","author":"Alberts","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0078","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00259-019-04552-9","article-title":"The role of additional late PSMA-ligand PET\/CT in the differentiation between lymph node metastases and ganglia","volume":"47","author":"Alberts","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0079","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41824-023-00166-5","article-title":"Is there more than meets the eye in PSMA imaging in prostate cancer with PET\/MRI? Looking closer at uptake time, correlation with PSA and Gleason score","volume":"7","author":"Bogdanovic","year":"2023","journal-title":"Eur J Hybrid Imaging"},{"issue":"9","key":"10.1053\/j.semnuclmed.2026.05.005_bib0080","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s00259-020-05086-1","article-title":"Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET\/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal 18F-fluorocholine PET\/CT: 1084 examinations","volume":"48","author":"Chevalme","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1053\/j.semnuclmed.2026.05.005_bib0081","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.crad.2017.06.116","article-title":"Early 68GA-PSMA PET\/MRI acquisition: assessment of lesion detectability and PET metrics in patients with prostate cancer undergoing same-day late PET\/CT","volume":"72","author":"Domachevsky","year":"2017","journal-title":"Clin radiol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.05.005_bib0082","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2214\/AJR.21.25961","article-title":"Reduced acquisition time per bed position for PET\/MRI using 68Ga-RM2 or 68Ga-PSMA-11 in patients with prostate cancer: a retrospective analysis","volume":"218","author":"Duan","year":"2022","journal-title":"Am J Roentgenol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0083","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101293","article-title":"68Ga-PSMA11 PET\/CT for biochemically recurrent prostate cancer: influence of dual-time and PMT-vs SiPM-based detectors","volume":"15","author":"Duan","year":"2022","journal-title":"Transl Oncol"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0084","doi-asserted-by":"crossref","DOI":"10.1177\/1536012118811741","article-title":"Scatter artifact with Ga-68-PSMA-11 PET: severity reduced with furosemide diuresis and improved scatter correction","volume":"17","author":"Lawhn-Heath","year":"2018","journal-title":"Mol Imaging"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.05.005_bib0085","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s11307-021-01670-5","article-title":"A pilot study of dynamic 18F-DCFPyL PET\/CT imaging of prostate adenocarcinoma in high-risk primary prostate cancer patients","volume":"24","author":"Lu","year":"2022","journal-title":"Mol Imaging Biol"},{"issue":"10","key":"10.1053\/j.semnuclmed.2026.05.005_bib0086","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164392","article-title":"Optimization of acquisition time of 68Ga-PSMA-ligand PET\/MRI in patients with local and metastatic prostate cancer","volume":"11","author":"L\u00fctje","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0087","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13550-022-00885-z","article-title":"Is there a diagnostic benefit of late-phase abdomino-pelvic PET\/CT after urination as part of whole-body 68 Ga-PSMA-11 PET\/CT for restaging patients with biochemical recurrence of prostate cancer after radical prostatectomy?","volume":"12","author":"Morawitz","year":"2022","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0088","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40658-020-00322-x","article-title":"68 Ga-PSMA-11 PET\/MRI: determining ideal acquisition times to reduce noise and increase image quality","volume":"7","author":"Murthy","year":"2020","journal-title":"EJNMMI Phys"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0089","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-017-0261-8","article-title":"Impact of PET acquisition durations on image quality and lesion detectability in whole-body 68 Ga-PSMA PET-MRI","volume":"7","author":"Noto","year":"2017","journal-title":"EJNMMI Res"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.05.005_bib0090","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4103\/ijnm.IJNM_32_18","article-title":"Can early dynamic positron emission tomography\/computed tomography obviate the need for postdiuresis image in 68Ga-PSMA-HBED-CC scan for evaluation of prostate adenocarcinoma?","volume":"33","author":"Perveen","year":"2018","journal-title":"Indian J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0091","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-020-0593-7","article-title":"Optimization of PET protocol and interrater reliability of 18 F-PSMA-11 imaging of prostate cancer","volume":"10","author":"Piron","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0092","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.657619","article-title":"Optimized application of 68Ga-prostate-specific membrane antigen-617 whole-body PET\/CT and pelvic PET\/MR in prostate cancer initial diagnosis and staging","volume":"8","author":"Qin","year":"2021","journal-title":"Front Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2026.05.005_bib0093","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.21037\/qims-20-1312","article-title":"Biphasic GA 68-labeled prostate specific membrane antigen-11 positron emission tomography\/computed tomography scans in the differential diagnosis and risk stratification of initial primary prostate cancer","volume":"11","author":"Qin","year":"2021","journal-title":"Quant Imaging Med Surg"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0094","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00259-018-3989-0","article-title":"18 F-PSMA-1007 PET\/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics","volume":"45","author":"Rahbar","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.05.005_bib0095","first-page":"351","article-title":"68Ga-PSMA-11 PET\/CT in prostate cancer local recurrence: impact of early images and parametric analysis","volume":"8","author":"Sachpekidis","year":"2018","journal-title":"Am j nucl med mol imaging"},{"issue":"11","key":"10.1053\/j.semnuclmed.2026.05.005_bib0096","doi-asserted-by":"crossref","DOI":"10.1097\/RLU.0000000000001349","article-title":"68Ga-PSMA-11 dynamic PET\/CT imaging in primary prostate cancer","volume":"41","author":"Sachpekidis","year":"2016","journal-title":"Clin nucl med"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0097","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1007\/s00259-015-3302-4","article-title":"68 Ga-PSMA-11 dynamic PET\/CT imaging in biochemical relapse of prostate cancer","volume":"43","author":"Sachpekidis","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0098","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s00259-019-04569-0","article-title":"18 F-PSMA-1007 multiparametric, dynamic PET\/CT in biochemical relapse and progression of prostate cancer","volume":"47","author":"Sachpekidis","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0099","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s00259-015-3251-y","article-title":"Biphasic 68 Ga-PSMA-HBED-CC-PET\/CT in patients with recurrent and high-risk prostate carcinoma","volume":"43","author":"Sahlmann","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"10.1053\/j.semnuclmed.2026.05.005_bib0100","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1007\/s00259-021-05420-1","article-title":"Pharmacokinetic studies of [68 Ga] Ga-PSMA-11 in patients with biochemical recurrence of prostate cancer: detection, differences in temporal distribution and kinetic modelling by tissue type","volume":"48","author":"Strauss","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.05.005_bib0101","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.2214\/AJR.17.18881","article-title":"Effect of combined 68Ga-PSMAHBED-CC uptake pattern and multiparametric MRI derived with simultaneous PET\/MRI in the diagnosis of primary prostate cancer: initial experience","volume":"210","author":"Taneja","year":"2018","journal-title":"Am J Roentgenol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.05.005_bib0102","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41391-022-00534-5","article-title":"The differential diagnostic value of dual-phase 18F-DCFPyL PET\/CT in prostate carcinoma","volume":"25","author":"Tian","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0103","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00259-020-04846-3","article-title":"Impact of forced diuresis with furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on [68 Ga] Ga-PSMA-11-PET\/CT in the evaluation of prostate cancer patients","volume":"48","author":"Uprimny","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1053\/j.semnuclmed.2026.05.005_bib0104","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.2967\/jnumed.120.261866","article-title":"Early injection of furosemide increases detection rate of local recurrence in prostate cancer patients with biochemical recurrence referred for 68Ga-PSMA-11 PET\/CT","volume":"62","author":"Uprimny","year":"2021","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.05.005_bib0105","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/MNM.0000000000001007","article-title":"Effect of forced diuresis during 18F-DCFPyL PET\/CT in patients with prostate cancer: activity in ureters, kidneys and bladder and occurrence of halo artefacts around kidneys and bladder","volume":"40","author":"Wondergem","year":"2019","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-021-00844-0","article-title":"Short-duration dynamic [18 F] DCFPyL PET and CT perfusion imaging to localize dominant intraprostatic lesions in prostate cancer: validation against digital histopathology and comparison to [18 F] DCFPyL PET\/MR at 120 minutes","volume":"11","author":"Yang","year":"2021","journal-title":"EJNMMI Res"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0107","doi-asserted-by":"crossref","first-page":"8297","DOI":"10.1038\/s41598-023-35628-0","article-title":"Diagnostic value of two-time point [68Ga] Ga-PSMA-11 PET\/CT in the primary staging of untreated prostate cancer","volume":"13","author":"Weitzer","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.05.005_bib0108","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1148\/radiol.2018172232","article-title":"Gallium 68 PSMA-11 PET\/MR imaging in patients with intermediate-or high-risk prostate cancer","volume":"288","author":"Park","year":"2018","journal-title":"Radiology"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0109","first-page":"11","article-title":"Role of 18 F-DCFPyL PET\/CT in patients with suspected prostate cancer","volume":"25","author":"Zhang","year":"2022","journal-title":"Hell J Nucl Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2026.05.005_bib0110","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s12149-023-01864-7","article-title":"Enhancing PSMA PET\/CT imaging of prostate cancer: investigating the impact of multiple time point evaluation, diuretic administration, cribriform pattern, and intraductal carcinoma","volume":"37","author":"Guner","year":"2023","journal-title":"Ann Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.05.005_bib0111","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2967\/jnmt.120.261289","article-title":"Correlation of lesional uptake parameters and ratios with miPSMA score and estimating normal physiologic concentration: an exploratory analysis in metastatic castration-resistant prostatic carcinoma patients with (68)Ga-PSMA-11 PET\/CT","volume":"49","author":"Kalshetty","year":"2021","journal-title":"J Nucl Med Technol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0112","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s41824-024-00217-5","article-title":"(18)F]AlF-PSMA-11 PET in diagnosing prostate cancer: a head-to-head comparison with [(68)Ga]Ga-PSMA-11 PET and an exploration of dual-phase scanning","volume":"8","author":"Li","year":"2024","journal-title":"EJNMMI Rep"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.05.005_bib0113","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2967\/jnumed.124.268574","article-title":"Diuresis during (18)F-flotufolastat (rhPSMA-7.3) PET\/CT improves recurrence detection after prostatectomy: a prospective phase II trial","volume":"66","author":"Lawal","year":"2025","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0114","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13550-024-01076-8","article-title":"The image quality and feasibility of solitary delayed [(68) Ga]Ga-PSMA-11 PET\/CT using long field-of-view scanning in patients with prostate cancer","volume":"14","author":"Yu","year":"2024","journal-title":"EJNMMI Res"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0115","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13550-025-01271-1","article-title":"The impact of patient hydration and forced diuresis on [(18)F]PSMA-1007 urinary bladder uptake in PET\/CT imaging","volume":"15","author":"Khalimon","year":"2025","journal-title":"EJNMMI Res"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.05.005_bib0116","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00259-024-06980-8","article-title":"Comparison of clinical performance between late and standard total-body [(68) Ga]Ga-PSMA-11 in biochemical recurrent prostate cancer","volume":"52","author":"Chen","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.05.005_bib0117","first-page":"107","article-title":"Bladder activity of different PSMA PET radioligands and impact of furosemide","volume":"16","author":"Lawal","year":"2026","journal-title":"Res Sq"},{"issue":"9","key":"10.1053\/j.semnuclmed.2026.05.005_bib0119","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s12149-024-01939-z","article-title":"Dual-time-point dynamic (68)Ga-PSMA-11 PET\/CT for parametric imaging generation in prostate cancer","volume":"38","author":"Burasothikul","year":"2024","journal-title":"Ann Nucl Med"},{"issue":"9","key":"10.1053\/j.semnuclmed.2026.05.005_bib0120","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1007\/s00261-024-04269-w","article-title":"Diagnostic value of dual-time point (68)Ga-PSMA PET\/CT image for benign and malignant lesions in patients with prostate cancer","volume":"49","author":"Xiao","year":"2024","journal-title":"Abdom Radiol (NY)"},{"issue":"7","key":"10.1053\/j.semnuclmed.2026.05.005_bib0121","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/MNM.0000000000001851","article-title":"Predictive significance of intraprostatic volumetric parameters derived from early and standard time 68Ga-PSMA PET\/CT images in newly diagnosed prostate cancer patients","volume":"45","author":"Erdogan","year":"2024","journal-title":"Nucl Med Commun"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.05.005_bib0122","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12149-024-02000-9","article-title":"Comparison of early and standard (18)F-PSMA-11 PET\/CT imaging in treatment-na\u00efve patients with prostate cancer","volume":"39","author":"Sun","year":"2025","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0123","article-title":"Head-to-head comparison of (68)Ga-PSMA-11 and (18)F-FDG in delayed PET\/CT imaging in prostate cancer diagnosis","volume":"15","author":"Hu","year":"2025","journal-title":"Front Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0124","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13550-025-01252-4","article-title":"Biphasic contrast-enhanced [(18)F]PSMA-1007 PET\/CT imaging to improve the detection of local relapse of prostate cancer","volume":"15","author":"Mamlins","year":"2025","journal-title":"EJNMMI Res"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0125","first-page":"127","article-title":"Value of two-phase [68 Ga] Ga-PSMA PET\/CT imaging in comparison with optimized delayed imaging in detecting locoregional prostatic metastases","volume":"33","author":"Fallahi","year":"2025","journal-title":"Iran J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0126","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41824-025-00238-8","article-title":"Impact of delayed pelvic imaging on the staging of biochemical recurrence in prostate cancer patients using [(18)F]DCFPYL PET\/CT: a retrospective evaluation","volume":"9","author":"Rodr\u00edguez-Pajuelo","year":"2025","journal-title":"EJNMMI Rep"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0127","first-page":"1","article-title":"Improved accuracy and reliability of PRIMARY scoring using delayed [(68)Ga] Ga-PSMA PET\/CT imaging","volume":"34","author":"Ak\u00e7ay","year":"2025","journal-title":"Mol Imaging Radionucl Ther"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.05.005_bib0128","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/MNM.0000000000001771","article-title":"Impact of forced diuresis at two different time points on pelvic imaging in prostatic carcinoma with 68 Ga-PSMA PET\/CT","volume":"44","author":"Raju","year":"2023","journal-title":"Nucl Med Commun"},{"issue":"9","key":"10.1053\/j.semnuclmed.2026.05.005_bib0129","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s00259-016-3419-0","article-title":"Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing","volume":"43","author":"Afshar-Oromieh","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"10.1053\/j.semnuclmed.2026.05.005_bib0130","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1007\/s00259-021-05438-5","article-title":"Feasibility of late acquisition [68Ga]Ga-PSMA-11 PET\/CT using a long axial field-of-view PET\/CT scanner for the diagnosis of recurrent prostate cancer-first clinical experiences","volume":"48","author":"Alberts","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.05.005_bib0131","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2967\/jnumed.119.227520","article-title":"Simplified methods for quantification of (18)F-DCFPyL uptake in patients with prostate cancer","volume":"60","author":"Jansen","year":"2019","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.05.005_bib0132","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1007\/s00330-016-4308-4","article-title":"(68)Ga-PSMA I&T PET\/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging","volume":"26","author":"Derlin","year":"2016","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0133","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13550-022-00938-3","article-title":"Evaluation of [(68) Ga]Ga-PSMA-I&T PET\/CT with additional late scans of the pelvis in prostate-specific antigen recurrence using the PROMISE criteria","volume":"12","author":"Koehler","year":"2022","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2026.05.005_bib0134","article-title":"The importance of late imaging associated with the use of diuretics in PET\/CT. 68Ga-PSMA in biochemical recurrence of prostate cancer","author":"Kurkowski","year":"2020","journal-title":"Sociedade Brasileira de Medicina Nuclear, S\u00e3o Paulo, SP (Brazil)"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0135","first-page":"63","article-title":"\u0421\u0440\u0430\u0432\u043d\u0438\u0442\u0435\u043b\u044c\u043d\u0430\u044f \u043e\u0446\u0435\u043d\u043a\u0430 \u0431\u0438\u043e\u0440\u0430\u0441\u043f\u0440\u0435\u0434\u0435\u043b\u0435\u043d\u0438\u044f 18F-\u041f\u0421\u041c\u0410-1007 \u0447\u0435\u0440\u0435\u0437 60 \u0438 120 \u043c\u0438\u043d\u0443\u0442 \u043f\u043e\u0441\u043b\u0435 \u0432\u043d\u0443\u0442\u0440\u0438\u0432\u0435\u043d\u043d\u043e\u0433\u043e \u0432\u0432\u0435\u0434\u0435\u043d\u0438\u044f \u043f\u0440\u0438 \u041f\u042d\u0422\/\u041a\u0422 \u0443 \u043f\u0430\u0446\u0438\u0435\u043d\u0442\u043e\u0432, \u043e\u0431\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u043d\u044b\u0445 \u043f\u043e \u043f\u043e\u0432\u043e\u0434\u0443 \u0440\u0430\u043a\u0430 \u043f\u0440\u0435\u0434\u0441\u0442\u0430\u0442\u0435\u043b\u044c\u043d\u043e\u0439 \u0436\u0435\u043b\u0435\u0437\u044b","volume":"14","author":"\u041b\u0435\u043e\u043d\u0442\u044c\u0435\u0432","year":"2023","journal-title":"\u041b\u0443\u0447\u0435\u0432\u0430\u044f \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0430 \u0438 \u0442\u0435\u0440\u0430\u043f\u0438\u044f"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0136","first-page":"6","article-title":"Comparison of tracer kinetic models for 68Ga-PSMA-11 PET in intermediate risk primary prostate cancer patients","volume":"14","author":"Smith","year":"2023","journal-title":"Res Sq"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.05.005_bib0137","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s12149-023-01823-2","article-title":"Multi-timepoint imaging with PSMA-targeted [(18)F]F-florastamin PET\/CT: lesion detection and comparison to conventional imaging","volume":"37","author":"Sheikhbahaei","year":"2023","journal-title":"Ann Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.05.005_bib0138","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","article-title":"Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer","volume":"17","author":"Szabo","year":"2015","journal-title":"Mol Imaging Biol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.05.005_bib0139","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2967\/jnumed.122.264743","article-title":"Phase III study of (18)F-PSMA-1007 versus (18)F-fluorocholine PET\/CT for localization of prostate cancer biochemical recurrence: a prospective, randomized, crossover multicenter study","volume":"64","author":"Olivier","year":"2023","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.05.005_bib0140","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/MNM.0000000000001770","article-title":"Comparison of 18F-PSMA-1007 and 18F-choline PET\/CT in prostate cancer patients with biochemical recurrence: a phase 3, prospective, multicenter, randomized study","volume":"44","author":"Panagiotidis","year":"2023","journal-title":"Nucl Med Commun"},{"issue":"7","key":"10.1053\/j.semnuclmed.2026.05.005_bib0141","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.2967\/jnumed.123.267271","article-title":"True-positive (18)F-flotufolastat lesions in patients with prostate cancer recurrence with baseline-negative conventional imaging: results from the prospective, phase 3, multicenter SPOTLIGHT study","volume":"65","author":"Fleming","year":"2024","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.05.005_bib0142","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.eururo.2023.06.018","article-title":"Diagnostic performance and safety of positron emission tomography with (18)F-rhPSMA-7.3 in patients with newly diagnosed unfavourable intermediate- to very-high-risk prostate cancer: results from a phase 3, prospective, multicentre study (LIGHTHOUSE)","volume":"84","author":"Surasi","year":"2023","journal-title":"Eur Urol"},{"issue":"10231","key":"10.1053\/j.semnuclmed.2026.05.005_bib0143","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1053\/j.semnuclmed.2026.05.005_bib0144","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","article-title":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial","volume":"7","author":"Hope","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.05.005_bib0145","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.euo.2023.11.008","volume":"7","author":"Buteau","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.05.005_bib0146","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with (18)F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"issue":"13","key":"10.1053\/j.semnuclmed.2026.05.005_bib0147","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic performance of (18)F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299826001121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299826001121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:32:09Z","timestamp":1792585929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299826001121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":145,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0001299826001121"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2026.05.005","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maximizing diagnostic yield: A systematic review and deep dive into PSMA PET scan protocol variations for prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2026.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}